Abstract

Objective: The adjuvant therapy for high-intermediate and high-risk endometrial cancer remains controversial. A recent randomized trial (PORTEC-3) reported that survival was improved with combination chemotherapy and radiotherapy, although the survival benefit was most pronounced in women with stage III tumors. We analyzed the association between multimodal therapy and survival for women with stage I–II high- and high-intermediate risk endometrial cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.